PELLFICURE
19 Apr 2022
Trial Summary
A Phase I Study of PCUR-101 in Combination with Androgen Directed Therapy in the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Acronym:
PELLFICURE
ACTRN/NCT /ethics:
NCT03137758
Scientific title:
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Sponsor / Cooperative group:
Pellficure Pharmaceuticals, Inc
Trial & Patient Characteristics
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Male |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2017-07-24 |
| Anticipated End Date | 2019-09-17 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Dr Sarwan Bishnoi |
| Recruitment Status | Recruiting |